Drug Trial Radar · NCT05203172
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Jul 5, 2022
Primary completion
Jul 31, 2029
Study completion Jun 30, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate in the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they were not enrolled in a prior study of encorafenib or binimetinib. Participants who had enrolled but had stopped receiving the study treatment in a prior study cannot be enrolled in this study. Participants in the FLOTILLA study will receive study treatment at the same dose and frequency as in their prior study, for up to about 5 years.
Conditions
- Solid Tumors
Interventions
BinimetinibDrug
Binimetinib is administered orally twice a day.
EncorafenibDrug
Encorafenib is administered orally once a day.
VemurafenibDrug
Vemurafenib is administered orally twice a day.
RibociclibDrug
Ribociclib is administered orally once a day.
CetuximabBiological
Cetuximab is administered intravenously (IV) every 2 weeks.
PembrolizumabBiological
Pembrolizumab is administered intravenously (IV) every 3 weeks. A maximum of 35 administrations will be given, including doses already given in the Parent Study.
NivolumabBiological
Nivolumab is administered intravenously (IV) every 4 week. A maximum of 24 months of treatment will be given, beginning with the first dose in the Parent Study.
5-FluorouracilDrug
5-FU is administered intravenously (IV) every 2 weeks.
LeucovorinDrug
Leucovorin is administered intravenously (IV) every 2 weeks. Levo-leucovorin may be given as an alternative for leucovorin.
OxaliplatinDrug
Oxaliplatin is administered intravenously (IV) every 2 or 3 weeks.
IrinotecanDrug
Irinotecan is administered intravenously (IV) every 2 weeks.
CapecitabineDrug
Capecitabine is administered orally twice a day for 14 consecutive days, followed by 7 days off.
BevacizumabBiological
Bevacizumab will be administered intravenously (IV), if applicable.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events leading to permanent discontinuation of study interventionTime frame: Baseline up to approximately 5 years
- Number serious adverse events reported for all participantsTime frame: Baseline up to approximately 5 years
Locations
77 sites in 20 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
St. Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Investigational Drug Service Emory University Clinic
Atlanta, Georgia · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
HealthPartners Cancer Research Center
Saint Paul, Minnesota · Recruiting
Regions Hospital Pharmacy
Saint Paul, Minnesota · Recruiting
Siteman Cancer Center
St Louis, Missouri · Recruiting
Barnes-Jewish Hospital
St Louis, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Washington University
St Louis, Missouri · Recruiting
MSK Basking Ridge
Basking Ridge, New Jersey · Active not recruiting
Rockefeller Outpatient Pavilion (53rd Street)
New York, New York · Active not recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Active not recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
Investigational Chemotherapy Service
Durham, North Carolina · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Liga Norte Riograndense Contra o Câncer
Natal, Rio Grande do Norte, Brazil · Recruiting
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Ijuí, Rio Grande do Sul, Brazil · Recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Not yet recruiting
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil · Recruiting
BP - A Beneficencia Portuguesa de São Paulo
São Paulo, São Paulo, Brazil · Recruiting
Real e Benemerita Associacao Portuguesa de Beneficencia
São Paulo, São Paulo, Brazil · Recruiting
University Health Network
Toronto, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Jewish General Hospital
Montreal, Quebec, Canada · Recruiting
Fakultni nemocnice Olomouc
Olomouc, Czechia · Recruiting
Lekarna Fakultni nemocnice Olomouc
Olomouc, Czechia · Recruiting
Vseobecna fakultni nemocnice v Praze
Prague, Praha 2, Czechia · Recruiting
Hopital Claude Huriez - CHU de Lille
Lille, NORD, France · Active not recruiting
Gustave Roussy
Villejuif, Val-de-marne, France · Active not recruiting
Charité Universitaetsmedizin Berlin - Campus Mitte
Berlin, Germany · Recruiting
Universitaetsklinikum Tuebingen
Tübingen, Baden-Wurttemberg, Germany · Active not recruiting
Otto-von-Guericke-Universitat Magdeburg
Magdeburg, Saxony-Anhalt, Germany · Active not recruiting
General Hospital of Athens ''Laiko''
Athens, Attikí, Greece · Recruiting
General Hospital of Athens "Laiko"
Athens, Attikí, Greece · Recruiting
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary · Recruiting
Pécsi Tudományegyetem Klinikai Központ
Pécs, Baranya, Hungary · Recruiting
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.